INFLUENCE OF THE N-ACETYLGLUCOSAMINE AND QUERCETIN COMBINATION IN THE INJECTABLE DOSAGE FORM ON THE COURSE OF ISCHEMIC ACUTE KIDNEY INJURY IN RATS

  • S. K. Shebeko NATIONAL UNIVERSITY OF PHARMACY, KHARKIV
  • I. A. Zupanets NATIONAL UNIVERSITY OF PHARMACY, KHARKIV
  • T. S. Sakharova NATIONAL UNIVERSITY OF PHARMACY, KHARKIV
Keywords: N-acetylglucosamine, quercetin, injectable dosage form, acute kidney injury

Abstract

Introduction. Optimization of the treatment of acute kidney injury (AKI) is an important medical and pharmaceutical problem. AKI is a common complication not only of kidney diseases, but also of various treatment methods. Mortality caused by AKI reaches 80 % in some groups of patients. Therefore, the search for effective agents for AKI treatment is an important task of modern experimental pharmacology. A promising approach in the solution of this problem may be the implementation of pharmaceutical combination of flavonoid quercetin and amino sugar N-acetylglucosamine in injectable dosage form.

The aim of the study – experimental study of the efficacy of N-acetylglucosamine and quercetin combination in injectable dosage form under the condition of ischemic AKI.

Research Methods. Studies were performed on a model of ischemic AKI in rats, which was induced by total occlusion of the renal blood vessels for 75 minutes. The test combination was studied at a dose of 30 mg/kg with daily intravenous (i.v.) administration for 3 days in comparison with quercetin (“Corvitin” medication), which was injected i.v. at a dose of 34 mg/kg. The efficacy of test drugs was assessed by the animal functional state, excretory renal function and nitrogen metabolism indicators.

Results and Discussion. Under the influence of test combination, there was a significant decrease (p<0.05) in mortality rate in rats with AKI compared to untreated animals, a decrease in diuresis by 1.5 times and proteinuria by 2.4 times, an increase in glomerular filtration by 3.0 times and tubular reabsorption by 9.9 %, creatinine and urea excretion were increased by 1.4 and 1.9 times, respectively, which indicates the normalization of kidney functional state and nitrogen metabolism. Moreover, the combination was significantly (p<0.05) superior to the Corvitin effect in efficacy level by all studied parameters.

Conclusions. Thus, the N-acetylglucosamine and quercetin combination is an effective agent for AKI treatment, which can be used at i.v. administration. It is advisable to further study of this drug as a therapy for renal pathology.

References

Lerma, E., Sparks, M., & Topf, J. (2019). Nephrology Secrets (4th еd.). Philadelphia: Elsevier.

Feehally, J., Floege, J., Johnson, R. J., & Tonelli, M. (2019). Comprehensive Clinical Nephrology (6th ed.). Philadelphia: Elsevier.

Anand, D.A.V., Arulmol, R., & Parasuraman, S. (2016). Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacognosy Review, 10 (20), 84-89.

Shebeko, S.K., Zupanets, I.A., Popov, O.S., Tarasenko, O.O., & Shalamay, A.S. (2018). Effects of Quercetin and Its Combinations on Health. Watson, R.R., Preedy, R.V., Zibadi, S. (Eds.). Polyphenols: Mechanisms of Action in Human Health and Disease (2nd ed., pp. 373-394). London: Academic Press.

Zupanets, I.A., & Shebeko, S.K. (2006). Dinamika soderzhaniya endogennogo glyukozamina u laboratornykh zhivotnykh s nefropatiey pod vozdeystviyem eksperi­mentalnoy terapii [The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy]. Eksperimentalnaya i klinicheskaya farmakologiya – Experimental and Clinical Pharmacology, 69 (6), 40-42 [in Russian].

Shebeko, S.K., & Zupanets, I.A. (2006). Dosli­dzhennia farmakolohichnykh vlastyvostei deiakykh po­khidnykh hliukozaminu v umovakh rozvytku ekspery­mentalnoho autoimunnoho hlomerulonefrytu [Study of the pharmacological properties of some glucosamine derivatives under conditions of development of expe­ri­men­tal autoimmune glomerulonephritis]. Klinichna farma­tsiia – Clinical Pharmacy, 10 (2), 31-35 [in Ukrainian].

Baynes, J.W., & Dominiczak, M.H. (2019). Medical Biochemistry (5th ed.). Philadelphia: Elsevier.

Guide for the care and use of laboratory animals (8th ed.). (2011). Washington: The National Academies Press.

Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes (2010). Official Journal of the European Union, L276, 33-79.

Shtryhol, S.Yu., Lisovyi, V.M., Zupanets, I.A., Shebeko, S.K., Maslova, N.F., Hozhenko, A.I., … Harchenko, D.S. (2009). Metody eksperymentalnoho modeliuvannia urazhennia nyrok dlia farmakolohichnykh doslidzhen: metodychni rekomendatsii [Methods of experimental modeling of kidney injury for pharmacological researches: methodical recommendations]. Kharkiv: Vydavnytstvo NFaU [in Ukrainian].

Kamyshnikov, V.S. (2016). Metody klinicheskikh laboratornykh issledovaniy [Methods of clinical laboratory tests]. Moscow: MEDpress-inform [in Russian].

Islam, M.A., & Al-Shiha, A. (2018). Foundations of Biostatistics. Singapore: Springer.

Yang, H., Song, Y., Liang, Y.N., & Li, R. (2018). Quercetin treatment improves renal function and protects the kidney in a rat model of adenine-induced chronic kidney disease. Med. Sci. Monit., 24, 4760-4766.

Layal, K., Perdhana, I.S., Louisa, M., Estu­ningtyas, A., & Soetikno, V. (2017). The effects of quercetin on oxidative stress and fibrosis markers in chronic kidney disease rat model. Med. J. Indones., 26, 169-177.

Vargas, F., Romecín, P., García-Guillén, A.I., Wangesteen, R., Vargas-Tendero, P., Paredes, M.D., … García-Estañ, J. (2018). Flavonoids in kidney health and disease. Front. Physiol., 9, 394.

Park, J., Lee, S.Y., Ooshima, A., Yang, K.M., Kang, J.M., Kim, Y.W., & Kim, S.J. (2013). Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-β signaling. Journal of Molecular Medicine, 91 (11), 1273-1284.

Hu, J., Chen, R., Jia, P., Fang, Y., Liu, T., Song, N., … Ding, X. (2017). Augmented O-GlcNAc signaling via glucosamine attenuates oxidative stress and apoptosis following contrast-induced acute kidney injury in rats. Free Radic. Biol. Med., 103, 121-132.

Wang, X., Xiong, M., Zeng, Y., Sun, X., Gong, T., Zhang, Z. (2014). Mechanistic studies of a novel myco­phenolic acid-glucosamine conjugate that attenuates renal ischemia/reperfusion injury in rat. Mol. Pharm., 11, 3503-3514.

Fu, Y., Lin, Q., Gong, T., Sun, X., & Zhang, Z.R. (2016). Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats. Acta Pharma­col. Sin., 37 (11), 1467-1480.

Morita, H., Yoshimura, A., Kimata, K. (2008). The role of heparan sulfate in the glomerular basement membrane. Kidney International, 73, 247-248.

Published
2019-11-07
How to Cite
Shebeko, S. K., Zupanets, I. A., & Sakharova, T. S. (2019). INFLUENCE OF THE N-ACETYLGLUCOSAMINE AND QUERCETIN COMBINATION IN THE INJECTABLE DOSAGE FORM ON THE COURSE OF ISCHEMIC ACUTE KIDNEY INJURY IN RATS. Medical and Clinical Chemistry, (3), 5-12. https://doi.org/10.11603/mcch.2410-681X.2019.v.i3.10554
Section
ORIGINAL INVESTIGATIONS